Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence (Q37976344)

26 August 2017

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence (English)

1 reference

26 August 2017

0 references

1 reference

1

G Giovannoni

1 reference

26 August 2017

3

E Waubant

1 reference

26 August 2017

E Southam

2

1 reference

26 August 2017

16 January 2012

1 reference

Multiple Sclerosis Journal

26 August 2017

1 reference

26 August 2017

18

1 reference

26 August 2017

7

1 reference

26 August 2017

932-946

1 reference

Interferons in relapsing remitting multiple sclerosis: a systematic review

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Glatiramer acetate for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Mitoxantrone: a review of its use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The contribution of observational studies to the knowledge of drug effectiveness in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Comparison of effects in randomized controlled trials with observational studies in digestive surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta treatment in relapsing-remitting multiple sclerosis: a post-marketing study in Lombardia, Italy. Multiple Sclerosis Centers of Lombardia, Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Long-term interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

To treat or not to treat the person with clinical multiple sclerosis--a dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Identification and development of new therapeutics for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Patient satisfaction with an injection device for multiple sclerosis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Multiple sclerosis: disability profile and quality of life in an Australian community cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon treatment may trigger primary headaches in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Quantitative risk-benefit analysis of natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Interferon beta in relapsing–remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511433302

21 January 2018

Identifiers

DOI

10.1177/1352458511433302

1 reference

26 August 2017

1 reference

PubMed ID

22249762